Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion type Assertion NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_head.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion description "[In view of these findings, the anti-CD20 chimeric monoclonal antibody, rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA), has been evaluated in the treatment of Waldenstrom's macroglobulinemia and multiple myeloma, as well as in nonmalignant plasma cell disorders including IgM polyneuropathies, immune thrombocytopenias, and autoimmune hemolytic anemias, with reported activity in these entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_provenance.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion evidence source_evidence_literature NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_provenance.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion SIO_000772 11226004 NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_provenance.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion wasDerivedFrom befree-20150227 NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_provenance.
- NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_assertion wasGeneratedBy ECO_0000203 NP911224.RATMvbquNwyrGNGljBO3OSyN-3-jtGG0okwMTv-LKqnK8130_provenance.